Tislelizumab Approved for First-Line in ESCC

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death ligand-1 (PD-L1; ≥ 1). The new approval is the Chinese immune checkpoint inhibitor’s third within a year…